Published in Annu Rev Physiol on January 01, 2005
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Nodes of Ranvier and axon initial segments are ankyrin G-dependent domains that assemble by distinct mechanisms. J Cell Biol (2007) 2.05
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2007) 1.99
Nectin-like proteins mediate axon Schwann cell interactions along the internode and are essential for myelination. J Cell Biol (2007) 1.63
Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood (2009) 1.40
Lung epithelium as a sentinel and effector system in pneumonia--molecular mechanisms of pathogen recognition and signal transduction. Respir Res (2006) 1.39
Heritable and stable gene knockdown in rats. Proc Natl Acad Sci U S A (2006) 1.26
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2008) 1.16
TNFalpha siRNA reduces brain TNF and EEG delta wave activity in rats. Brain Res (2007) 1.11
REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur J Neurosci (2006) 1.11
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc Natl Acad Sci U S A (2006) 1.08
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
Polymersome delivery of siRNA and antisense oligonucleotides. J Control Release (2008) 1.04
Simultaneous silencing of Npy and Dbh expression in hindbrain A1/C1 catecholamine cells suppresses glucoprivic feeding. J Neurosci (2009) 0.96
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood (2014) 0.94
Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. Eur J Neurosci (2010) 0.91
Stable silencing of SNAP-25 in PC12 cells by RNA interference. BMC Neurosci (2006) 0.88
Synthetic Tet-inducible artificial microRNAs targeting β-catenin or HIF-1α inhibit malignant phenotypes of bladder cancer cells T24 and 5637. Sci Rep (2015) 0.85
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics (2009) 0.82
Toward personalized cancer nanomedicine - past, present, and future. Integr Biol (Camb) (2013) 0.80
Knockdown of orexin type 2 receptor in the lateral pontomesencephalic tegmentum of rats increases REM sleep. Eur J Neurosci (2013) 0.78
Silencing the NR2B gene in rat ACC neurons by lentivirus-delivered shRNA alleviates pain-related aversion. Int J Clin Exp Med (2015) 0.75
Cadm3 (Necl-1) interferes with the activation of the PI3 kinase/Akt signaling cascade and inhibits Schwann cell myelination in vitro. Glia (2016) 0.75
RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi? Int J Mol Sci (2016) 0.75
A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet (2003) 12.16
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A (2004) 9.33
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med (2002) 3.80
Lamellipodin, an Ena/VASP ligand, is implicated in the regulation of lamellipodial dynamics. Dev Cell (2004) 2.96
Filopodia are required for cortical neurite initiation. Nat Cell Biol (2007) 2.49
A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat Immunol (2004) 2.30
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol (2003) 2.13
Ena/VASP Is Required for neuritogenesis in the developing cortex. Neuron (2007) 2.01
Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med (2003) 1.93
Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migration. Mol Biol Cell (2002) 1.81
Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem (2003) 1.57
The costimulation-regulated duration of PKB activation controls T cell longevity. Nat Immunol (2004) 1.57
A La protein requirement for efficient pre-tRNA folding. EMBO J (2003) 1.55
Ena/VASP is required for endothelial barrier function in vivo. J Cell Biol (2007) 1.53
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorg Med Chem (2010) 1.40
The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells. J Biol Chem (2003) 1.32
Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One (2009) 1.30
ARF is not required for apoptosis in Rb mutant mouse embryos. Curr Biol (2002) 1.30
αv Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice. J Clin Invest (2010) 1.23
Gas1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis. Blood (2003) 1.23
Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood (2012) 1.23
Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells. Proc Natl Acad Sci U S A (2002) 1.22
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol (2013) 1.18
The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function. J Biol Chem (2003) 1.18
IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol (2002) 1.16
Retracted Autoimmunity as the consequence of a spontaneous mutation in Rasgrp1. Immunity (2003) 1.15
ARF mutation accelerates pituitary tumor development in Rb+/- mice. Proc Natl Acad Sci U S A (2002) 1.15
STIM1-independent T cell development and effector function in vivo. J Immunol (2009) 1.15
Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol (2011) 1.12
Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets (2013) 1.12
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem (2012) 1.11
Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol (2013) 1.08
The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function. Diabetes (2011) 1.05
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
IL-17 silencing does not protect nonobese diabetic mice from autoimmune diabetes. J Immunol (2011) 1.03
Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des (2013) 1.01
The plant hormone abscisic acid increases in human plasma after hyperglycemia and stimulates glucose consumption by adipocytes and myoblasts. FASEB J (2011) 1.01
PTPN22 silencing in the NOD model indicates the type 1 diabetes-associated allele is not a loss-of-function variant. Diabetes (2012) 0.99
Reconstitution of lethally irradiated adult mice with dominant negative TGF-beta type II receptor-transduced bone marrow leads to myeloid expansion and inflammatory disease. J Immunol (2002) 0.97
NAD+ levels control Ca2+ store replenishment and mitogen-induced increase of cytosolic Ca2+ by Cyclic ADP-ribose-dependent TRPM2 channel gating in human T lymphocytes. J Biol Chem (2012) 0.96
Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res (2004) 0.94
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood (2013) 0.93
Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets (2010) 0.92
Epi-allelic Erk1 and Erk2 knockdown series for quantitative analysis of T cell Erk regulation and IL-2 production. Mol Immunol (2007) 0.92
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One (2011) 0.90
Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev (2007) 0.89
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib. Leuk Res (2010) 0.89
T cell costimulation through CD28 depends on induction of the Bcl-xgamma isoform: analysis of Bcl-xgamma-deficient mice. J Exp Med (2002) 0.88
RNA interference for the identification of disease-associated genes. Curr Opin Mol Ther (2004) 0.88
Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol (2012) 0.88
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol (2010) 0.88
Uterine peristaltic activity and the development of endometriosis. Ann N Y Acad Sci (2004) 0.87
Discovery of novel and selective SIRT6 inhibitors. J Med Chem (2014) 0.87
Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res (2002) 0.87
Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy (2013) 0.87
The effect of preoperative chemoradiotherapy on lymph nodes harvested in TME for rectal cancer. World J Surg Oncol (2013) 0.86
Cyclopentenone prostaglandins induce lymphocyte apoptosis by activating the mitochondrial apoptosis pathway independent of external death receptor signaling. J Immunol (2003) 0.85
Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm (2013) 0.85
APO866 activity in hematologic malignancies: a preclinical in vitro study. Blood (2009) 0.85
The vulnerable coronary plaque: update on imaging technologies. Thromb Haemost (2013) 0.84
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost (2014) 0.84
CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem (2013) 0.84
A transient transgenic RNAi strategy for rapid characterization of gene function during embryonic development. PLoS One (2010) 0.83
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disorders. Curr Top Med Chem (2013) 0.82
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res (2003) 0.82
Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost (2013) 0.82
TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells. Eur J Immunol (2014) 0.81
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leuk Lymphoma (2012) 0.81
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. Clin Dev Immunol (2011) 0.81
Glucagon-like peptide-1 triggers protective pathways in pancreatic beta-cells exposed to glycated serum. Mediators Inflamm (2013) 0.79
Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes. J Immunol (2003) 0.79
New insights into biology of chronic myeloid leukemia: implications in therapy. Curr Cancer Drug Targets (2013) 0.78
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. Curr Cancer Drug Targets (2013) 0.78
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate (2006) 0.78
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol (2007) 0.77
Correction: Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma. Elife (2016) 0.77
An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. Mediators Inflamm (2013) 0.77
Retraction. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity (2009) 0.77
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. Bioorg Med Chem Lett (2009) 0.77
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. Bioorg Med Chem (2011) 0.76
The role of proteasome in malignant diseases. J BUON (2007) 0.76
Selectivity hot-spots of sirtuin catalytic cores. Mol Biosyst (2015) 0.75
Exploring the genetic basis of disease using RNA interference. Expert Rev Mol Diagn (2004) 0.75
Retraction. Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity (2009) 0.75
Retraction. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity (2009) 0.75